{
    "clinical_study": {
        "@rank": "77116", 
        "arm_group": [
            {
                "arm_group_label": "inhaled Nitric Oxide", 
                "arm_group_type": "Experimental", 
                "description": "iNO to start at 20ppm for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued."
            }, 
            {
                "arm_group_label": "Nitrogen Gas", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo gas will be adjusted the same as study gas: to start at 20ppm for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to determine if inhaled nitric oxide will improve short and long\n      term respiratory outcomes in preterm infants.  Infants born at a gestational age of 30-36\n      weeks and who require breathing support with high flow nasal cannula, nasal continuous\n      positive airway pressure, or nasal intermittent positive pressure will be randomized to\n      receive either inhaled nitric oxide or placebo. The dose will then be decreased per protocol\n      until all respiratory support has been discontinued. Infants will be followed to evaluate\n      safety and efficacy of non-invasive iNO delivery, up to 12 months corrected gestational age."
        }, 
        "brief_title": "Study of Inhaled Nitric Oxide and Respiratory Outcomes in Late Preterm Infants", 
        "condition": "Bronchopulmonary Dysplasia", 
        "condition_browse": {
            "mesh_term": "Bronchopulmonary Dysplasia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  <48 hours of age,\n\n          -  30 - 36 weeks gestational age at birth based on best estimate using obstetrical\n             sonography (first or second trimester), solid dating criteria, or Ballard\n             examination,\n\n          -  Birth weight of \u2265 1,000 g,\n\n          -  5 minute Apgar score \u22655,\n\n          -  Requiring nasal cannula O2 > 1LPM, CPAP, or NIPPV for treatment of respiratory\n             failure,\n\n          -  Requiring a fraction of inspired oxygen (FIO2) of at least 0.25 to maintain SaO2\n             88-94%,\n\n          -  Parent or guardian has signed informed consent and agrees to all study- related\n             procedures, including those required after hospital discharge.\n\n        Exclusion Criteria:\n\n          -  Major congenital anomaly\n\n          -  Intubation and surfactant in the delivery room or prior to enrollment in the NICU.\n             Excludes intubation for suctioning.\n\n          -  Known congenital infection (bacterial, viral),\n\n          -  Perinatal asphyxia (5 minute Apgar <5, umbilical artery pH < 7.0 or evidence of\n             neonatal encephalopathy),\n\n          -  Mother and/or infant is enrolled in another clinical trial (excluding observational)\n             or has received an investigational drug,\n\n          -  Has undergone or is anticipated to require a major surgical procedure within the\n             first 48 h of life,\n\n          -  Any condition which could preclude receiving study drug or performing any\n             study-related procedures,\n\n          -  Use of postnatal corticosteroids,\n\n          -  Parent or guardian is unable or unwilling to complete study procedures after hospital\n             discharge."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "36 Weeks", 
            "minimum_age": "30 Weeks"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01748045", 
            "org_study_id": "10487"
        }, 
        "intervention": [
            {
                "arm_group_label": "inhaled Nitric Oxide", 
                "intervention_name": "inhaled nitric oxide", 
                "intervention_type": "Drug", 
                "other_name": "iNO, INOmax"
            }, 
            {
                "arm_group_label": "Nitrogen Gas", 
                "intervention_name": "Placebo Comparator - nitrogen gas", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Nitric Oxide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Inhaled Nitric Oxide", 
            "Bronchopulmonary Dysplasia", 
            "Late Prematurity", 
            "Chronic Respiratory Morbidity"
        ], 
        "lastchanged_date": "December 6, 2013", 
        "location": {
            "contact": {
                "email": "cdammann@tuftsmedicalcenter.org", 
                "last_name": "Christiane EL Dammann, MD", 
                "phone": "617-636-4191"
            }, 
            "contact_backup": {
                "email": "jdavis@tuftsmedicalcenter.org", 
                "last_name": "Jonathan M Davis, MD", 
                "phone": "6176364191"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02111"
                }, 
                "name": "Tufts Medical Center"
            }, 
            "investigator": {
                "last_name": "Christiane EL Dammann, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Use of Inhaled Nitric Oxide to Improve Respiratory Outcomes in Late Preterm Infants", 
        "overall_contact": {
            "email": "cdammann@tuftsmedicalcenter.org", 
            "last_name": "Christiane EL Dammann, MD", 
            "phone": "617-636-4191"
        }, 
        "overall_official": {
            "affiliation": "Tufts Medical Center", 
            "last_name": "Jennifer W Lee, MD, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Primary combined endpoint of alive without the need for intubation or mechanical ventilation within the first week of life", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01748045"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Need for exogenous surfactant", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "participants will be followed for the duration of hospital stay", 
                "measure": "Total length of hospital stay", 
                "safety_issue": "No", 
                "time_frame": "At hospital discharge, anticipate up to 10 weeks"
            }, 
            {
                "description": "participants will be followed for the duration of hospital stay for use of supplemental oxygen", 
                "measure": "Total duration of supplemental oxygen", 
                "safety_issue": "No", 
                "time_frame": "anticipate average 4 weeks"
            }, 
            {
                "description": "Diagnosis of BPD by oxygen challenge test at 36 weeks PMA for infants born between 30 and 32 weeks GA.  For those born 32 1/7 - 36 weeks, an oxygen challenge test will be performed at 1-2 months of age.", 
                "measure": "Diagnosis of BPD", 
                "safety_issue": "No", 
                "time_frame": "At 36 weeks postmenstrual age"
            }, 
            {
                "description": "defined by a validated system of parental diaries and pulmonary questionnaires, as well as review of medical records (medical visits, respiratory medication use, emergency room visits, and hospital re-admissions)", 
                "measure": "Evidence of chronic respiratory morbidity at 12 months CGA", 
                "safety_issue": "No", 
                "time_frame": "12 months corrected gestational age"
            }, 
            {
                "description": "participants will be followed for the duration of hospital stay for respiratory support", 
                "measure": "Total Duration of Respiratory Support", 
                "safety_issue": "No", 
                "time_frame": "anticipate average 4 weeks"
            }
        ], 
        "source": "Tufts Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Ikaria", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Tufts Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}